171 related articles for article (PubMed ID: 12374462)
1. The angiogenic factor Cyr61 is induced by the progestin R5020 and is necessary for mammary adenocarcinoma cell growth.
Sampath D; Winneker RC; Zhang Z
Endocrine; 2002 Jul; 18(2):147-59. PubMed ID: 12374462
[TBL] [Abstract][Full Text] [Related]
2. Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17beta-estradiol and overexpression in human breast cancer.
Sampath D; Winneker RC; Zhang Z
Endocrinology; 2001 Jun; 142(6):2540-8. PubMed ID: 11356703
[TBL] [Abstract][Full Text] [Related]
3. Progesterone augments proliferation induced by epidermal growth factor in a feline mammary adenocarcinoma cell line.
Modiano JF; Kokai Y; Weiner DB; Pykett MJ; Nowell PC; Lyttle CR
J Cell Biochem; 1991 Feb; 45(2):196-206. PubMed ID: 2055947
[TBL] [Abstract][Full Text] [Related]
4. Expression and regulation of Cyr61 in human breast cancer cell lines.
Tsai MS; Bogart DF; Li P; Mehmi I; Lupu R
Oncogene; 2002 Jan; 21(6):964-73. PubMed ID: 11840342
[TBL] [Abstract][Full Text] [Related]
5. Cyr61 promotes breast tumorigenesis and cancer progression.
Tsai MS; Bogart DF; Castañeda JM; Li P; Lupu R
Oncogene; 2002 Nov; 21(53):8178-85. PubMed ID: 12444554
[TBL] [Abstract][Full Text] [Related]
6. Progesterone agonists and antagonists induce down- and up-regulation of estrogen receptors and estrogen inducible genes in human breast cancer cell lines.
Savoldi G; Ferrari F; Ruggeri G; Sobek L; Albertini A; Di Lorenzo D
Int J Biol Markers; 1995; 10(1):47-54. PubMed ID: 7629427
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of T47D human breast cancer cell growth by the synthetic progestin R5020: effects of serum, estradiol, insulin, and EGF.
Gill PG; Tilley WD; De Young NJ; Lensink IL; Dixon PD; Horsfall DJ
Breast Cancer Res Treat; 1991 Dec; 20(1):53-62. PubMed ID: 1813069
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of Cyr61, a member of the CCN (CTGF/Cyr61/Cef10/NOVH) family, and dysregulation by 17 beta-estradiol and basic fibroblast growth factor in human uterine leiomyomas.
Sampath D; Zhu Y; Winneker RC; Zhang Z
J Clin Endocrinol Metab; 2001 Apr; 86(4):1707-15. PubMed ID: 11297607
[TBL] [Abstract][Full Text] [Related]
9. Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.
Gill PG; Vignon F; Bardon S; Derocq D; Rochefort H
Breast Cancer Res Treat; 1987 Oct; 10(1):37-45. PubMed ID: 3689980
[TBL] [Abstract][Full Text] [Related]
10. The FK506-binding immunophilin FKBP51 is transcriptionally regulated by progestin and attenuates progestin responsiveness.
Hubler TR; Denny WB; Valentine DL; Cheung-Flynn J; Smith DF; Scammell JG
Endocrinology; 2003 Jun; 144(6):2380-7. PubMed ID: 12746298
[TBL] [Abstract][Full Text] [Related]
11. Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model.
Raafat AM; Li S; Bennett JM; Hofseth LJ; Haslam SZ
J Cell Physiol; 2001 Apr; 187(1):81-9. PubMed ID: 11241352
[TBL] [Abstract][Full Text] [Related]
12. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives.
Menéndez JA; Mehmi I; Griggs DW; Lupu R
Endocr Relat Cancer; 2003 Jun; 10(2):141-52. PubMed ID: 12790776
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor suppresses induction by progestin of the adhesion protein desmoplakin in T47D breast cancer cells.
Pang H; Rowan BG; Al-Dhaheri M; Faber LE
Breast Cancer Res; 2004; 6(3):R239-45. PubMed ID: 15084247
[TBL] [Abstract][Full Text] [Related]
14. Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2.
Cui X; Lazard Z; Zhang P; Hopp TA; Lee AV
Oncogene; 2003 Oct; 22(44):6937-41. PubMed ID: 14534541
[TBL] [Abstract][Full Text] [Related]
15. A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway.
Menendez JA; Vellon L; Mehmi I; Teng PK; Griggs DW; Lupu R
Oncogene; 2005 Jan; 24(5):761-79. PubMed ID: 15592521
[TBL] [Abstract][Full Text] [Related]
16. Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells.
Hurd C; Nag K; Khattree N; Alban P; Dinda S; Moudgil VK
Mol Cell Biochem; 1999 Sep; 199(1-2):49-56. PubMed ID: 10544951
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer.
Jiang WG; Watkins G; Fodstad O; Douglas-Jones A; Mokbel K; Mansel RE
Endocr Relat Cancer; 2004 Dec; 11(4):781-91. PubMed ID: 15613452
[TBL] [Abstract][Full Text] [Related]
18. Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progestin- and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells.
Le Bihan S; Marsaud V; Mercier-Bodard C; Baulieu EE; Mader S; White JH; Renoir JM
Mol Endocrinol; 1998 Jul; 12(7):986-1001. PubMed ID: 9658403
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease.
Xie D; Miller CW; O'Kelly J; Nakachi K; Sakashita A; Said JW; Gornbein J; Koeffler HP
J Biol Chem; 2001 Apr; 276(17):14187-94. PubMed ID: 11297518
[TBL] [Abstract][Full Text] [Related]
20. Progestin inhibition of estrogen-dependent proliferation in ZR-75-1 human breast cancer cells: antagonism by insulin.
Poulin R; Dufour JM; Labrie F
Breast Cancer Res Treat; 1989 Jul; 13(3):265-76. PubMed ID: 2667655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
